Jump to: navigation, search
Monoclonal antibody
TypeWhole antibody
SourceTemplate:Infobox drug/mab source
Clinical data
Trade namesRaptiva
Routes of
subcutaneous injection
ATC code
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Melting point66 °C (150.8 °F)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Efalizumab


Most recent articles on Efalizumab

Most cited articles on Efalizumab

Review articles on Efalizumab

Articles on Efalizumab in N Eng J Med, Lancet, BMJ


Powerpoint slides on Efalizumab

Images of Efalizumab

Photos of Efalizumab

Podcasts & MP3s on Efalizumab

Videos on Efalizumab

Evidence Based Medicine

Cochrane Collaboration on Efalizumab

Bandolier on Efalizumab

TRIP on Efalizumab

Clinical Trials

Ongoing Trials on Efalizumab at Clinical Trials.gov

Trial results on Efalizumab

Clinical Trials on Efalizumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Efalizumab

NICE Guidance on Efalizumab


FDA on Efalizumab

CDC on Efalizumab


Books on Efalizumab


Efalizumab in the news

Be alerted to news on Efalizumab

News trends on Efalizumab


Blogs on Efalizumab


Definitions of Efalizumab

Patient Resources / Community

Patient resources on Efalizumab

Discussion groups on Efalizumab

Patient Handouts on Efalizumab

Directions to Hospitals Treating Efalizumab

Risk calculators and risk factors for Efalizumab

Healthcare Provider Resources

Symptoms of Efalizumab

Causes & Risk Factors for Efalizumab

Diagnostic studies for Efalizumab

Treatment of Efalizumab

Continuing Medical Education (CME)

CME Programs on Efalizumab


Efalizumab en Espanol

Efalizumab en Francais


Efalizumab in the Marketplace

Patents on Efalizumab

Experimental / Informatics

List of terms related to Efalizumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.[1] Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.[2][3] Four cases of PML were reported in plaque psoriasis patients, an incidence of approximately one in 500 treated patients.[1]

Due to the risk of PML, the European Medicines Agency and the FDA recommended suspension from the market in the European Union and the United States, respectively.[4] In April 2009, Genentech Inc. announced a phased voluntary withdrawal of Raptiva from the U.S. market.[1][5]


  1. 1.0 1.1 1.2 PMID 19719397 (PMID 19719397)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  2. "Efalizumab FDA Warning". Retrieved 7 December 2008.
  3. PMID 20073129 (PMID 20073129)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  4. "EMEA press release regarding suspension" (PDF). Retrieved 20 February 2009.
  5. "Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market" (Press release). Genentech, Inc. 8 April 2009. Retrieved 9 April 2009.